CTI BioPharma Corp.
NASDAQ: CTIC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adam R. Craig
- Employees
- 127
- Headquarters
- Seattle, United States
- IPO year
- 1997
- Market cap
- $1.2B
- Website
- https://www.ctibiopharma.com
Loading CTIC…
Loading profile data…Frequently asked questions about CTIC
What does CTI BioPharma Corp. (CTIC) do?
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1...
Where does CTIC trade?
CTI BioPharma Corp. (CTIC) trades on the NASDAQ Capital Market.
What sector is CTIC in?
CTI BioPharma Corp. (CTIC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CTI BioPharma Corp.?
Adam R. Craig is the chief executive officer of CTI BioPharma Corp. (CTIC).
Where is CTI BioPharma Corp. headquartered?
CTI BioPharma Corp. is headquartered in United States.
Does CTIC pay a dividend?
CTI BioPharma Corp. (CTIC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CTIC go public?
CTI BioPharma Corp. (CTIC) completed its initial public offering in 1997.